JPMorgan Reiterates $92 PT on Spring Works Therapeutics (SWTX), 'we continue to see underappreciated fundamental value with nirogacestat in desmoid tumors and BCMA programs'
Tweet Send to a Friend
JPMorgan analyst Anupam Rama reiterated an Overweight rating and $92.00 price target on Spring Works Therapeutics (NASDAQ: SWTX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
